Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease

International Journal of Cardiology

Volumn 118, Issue 2, 2007, Pages 215-219

  Wang, Shaoshan S ^a,b   Tondella, Maria Lucia C ^c   Bajpai, Ambar ^a,b   Mathew, Anil G ^a,b   Mehranpour, Payam ^a,b   Li, Wei ^a,b   Kacharava, Andro G ^a,b   Fields, Barry S ^c   Austin, Harland ^d   Zafari, A Maziar ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Coronary angiography; Coronary artery disease severity; Real time PCR

Indexed keywords

BACTERIAL DNA;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; BLOOD SAMPLING; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHLAMYDOPHILA PNEUMONIAE; CIRCULATION; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

BACTEREMIA; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COHORT STUDIES; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; DNA, BACTERIAL; FEMALE; GEORGIA; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 34247093349     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.07.013     Document Type: Article

References (41)

1. Kuo C.C., Jackson L.A., Campbell L.A., and Grayston J.T. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 8 (1995) 451-461
2. Kalayoglu M.V., Libby P., and Byrne G.I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288 (2002) 2724-2731
3. Saikku P., Leinonen M., Tenkanen L., et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 116 (1992) 273-278
4. Kuo C.C., Coulson A.S., Campbell L.A., et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 26 (1997) 29-31
5. Muhlestein J.B., Anderson J.L., Hammond E.H., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97 (1998) 633-636
6. Moazed T.C., Kuo C., Grayston J.T., and Campbell L.A. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 175 (1997) 883-890
7. O'Connor C.M., Dunne M.W., Pfeffer M.A., et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290 (2003) 1459-1466
8. Cannon C.P., Braunwald E., McCabe C.H., et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 352 (2005) 1646-1654
9. Grayston J.T., Kronmal R.A., Jackson L.A., et al., for the ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med 352 (2005) 1637-1645
10. Dowell S.F., Peeling R.W., Boman J., et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 33 (2001) 492-503
11. Tondella M.L., Talkington D.F., Holloway B.P., et al. Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae. J Clin Microbiol 40 (2002) 575-583
12. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 17 (1999) 151-183
13. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
14. Dash H., Johnson R.A., Dinsmore R.E., Francis C.K., and Harthorne J.W. Cardiomyopathic syndrome due to coronary artery disease. Br Heart J 39 (1977) 733-739
15. Califf R.M., Phillips III H.R., Hindman M.C., et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol 5 (1985) 1055-1063
16. Boman J., Soderberg S., Forsberg J., et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 178 (1998) 274-277
17. Muller J., Nyvad O., Larsen N.A., et al. Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in dialysis patients, renal transplant recipients and healthy controls. Scand J Clin Lab Invest 62 (2002) 503-509
18. Muller J., Moller D.S., Kjaer M., Nyvad O., Larsen N.A., and Pedersen E.B. Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in healthy control subjects and patients with diabetes mellitus, acute coronary syndrome, stroke, and arterial hypertension. Scand J Infect Dis 35 (2003) 704-712
19. Moazed T.C., Kuo C.C., Grayston J.T., and Campbell L.A. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis 177 (1998) 1322-1325
20. Maass M., Bartels C., Engel P.M., Mamat U., and Sievers H.H. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 31 (1998) 827-832
21. Blasi F., Boman J., Esposito G., et al. Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis 180 (1999) 2074-2076
22. Berger M., Schroder B., Daeschlein G., et al. Chlamydia pneumoniae DNA in non-coronary atherosclerotic plaques and circulating leukocytes. J Lab Clin Med 136 (2000) 194-200
23. + lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 102 (2000) 2341-2346
24. Wong Y.K., Dawkins K.D., and Ward M.E. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 34 (1999) 1435-1439
25. Hoymans V., Bosmans J., Ursi D., et al. Systemic inflammation, Chlamydia pneumoniae DNA in circulating leukocytes and coronary atherosclerosis. Acta Cardiol 57 (2002) 213-219
26. Smieja M., Mahony J., Petrich A., Boman J., and Chernesky M. Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect Dis 2 (2002) 21
27. Well B.J., Mainous A.G., and Dickerson L.M. Antibiotics for the secondary prevention of ischemic heart disease. A meta-analysis of randomized control trials. Arch Int Med 164 (2004) 2156-2161
28. Andraws R., Berger J.S., and Brown D.L. Effects of antibiotic therapy on outcomes of patients with coronary artery disease. A meta-analysis of randomized control trials. JAMA 293 (2005) 2641-2647
29. Higgins J.P. Chlamydia pneumoniae and coronary artery disease. Mayo Clin Proc 78 (2003) 321-332
30. Meier C.R. Antibiotics in the prevention and treatment of coronary heart disease. J Infect Dis 181 (2000) S558-S562
31. Gieffers J., Fullgraf H., Jahn J., et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103 (2001) 351-356
32. Muhlestein J.B., Hammond E.H., Carlquist J.F., et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 27 (1996) 1555-1561
33. Jackson L.A., Campbell L.A., Schmidt R.A., et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 150 (1997) 1785-1790
34. Bahrmand A.R., Bahadori M., Hossaini A., et al. Chlamydia pneumoniae DNA is more frequent in advanced than in mild atherosclerosis lesions. Scand J Infect Dis 36 (2004) 119-123
35. Sessa R., Di Pietro M., Schiavoni G., et al. Detection of Chlamydia pneumoniae in atherosclerotic coronary arteries. Int J Immunopathol Pharmacol 17 (2004) 301-306
36. Sessa R., Di Pietro M., Schiavoni G., et al. Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease. J Vasc Surg 37 (2003) 1027-1031
37. Moazed T.C., Campbell L.A., Rosenfeld M.E., Grayston J.T., and Kuo C.C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 180 (1999) 238-241
38. Chesebro B.B., Blessing E., Kuo C.C., Rosenfeld M.E., Puolakkainen M., and Campbell L.A. Nitric oxide synthase plays a role in Chlamydia pneumoniae-induced atherosclerosis. Cardiovasc Res 60 (2003) 170-174
39. Kalvegren H., Bylin H., Leanderson P., Richter A., Grenegard M., and Bengtsson T. Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins. Thromb Haemost 94 (2005) 327-335
40. Sawayama Y., Tatsukawa M., Okada K., et al. Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins. Atherosclerosis 171 (2003) 281-285
41. Anderson J.L. Infection, and atherothrombosis - end of the road or new beginnings?. N Engl J Med 352 (2005) 1706-1709